AXTLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AXTLE (AXTLE).
AXTLE is a monoclonal antibody that binds to and inhibits the activity of a specific cytokine or receptor, thereby modulating immune response or cell signaling pathways involved in disease pathology.
| Metabolism | Metabolized via nonspecific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Primarily renal elimination (70-80% unchanged); biliary/fecal excretion accounts for 15-20%; about 5% undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life is approximately 4-6 hours in patients with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl < 30 mL/min). |
| Protein binding | Approximately 65-75% bound to albumin; binding is concentration-independent. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating distribution into total body water; increased in edematous states. |
| Bioavailability | Oral: 50-65% due to first-pass metabolism; IM: 90-100%. |
| Onset of Action | Intravenous: 5-15 minutes; oral: 30-60 minutes; intramuscular: 15-30 minutes. |
| Duration of Action | IV/IM: 4-6 hours; oral: 6-8 hours; clinical effect may persist longer in renal impairment. |
| Molecular Weight | 327.4 |
10 mg orally once daily for 14 days, then 5 mg orally once daily for 14 days, then 2.5 mg orally once daily for 14 days; after 42 days, continue 2.5 mg orally once daily.
| Dosage form | POWDER |
| Renal impairment | GFR ≥60 mL/min: no adjustment. GFR 30-59 mL/min: reduce dose by 50%. GFR <30 mL/min: use with caution, maximum dose 2.5 mg daily. Not recommended in ESRD. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% of normal maximum. Child-Pugh C: not recommended. |
| Pediatric use | Not established for children <18 years; safety and efficacy not studied. |
| Geriatric use | Start at 5 mg once daily; titrate slowly based on tolerability; maximum 10 mg daily. |
| 1st trimester | Limited data: no adequate studies in humans; animal studies show risk. Avoid unless benefit outweighs risk. |
| 2nd trimester | Limited data: potential fetal effects; use only if clearly needed. |
| 3rd trimester | Avoid: may cause neonatal adverse effects (e.g., persistent pulmonary hypertension). |
Clinical note
Comprehensive clinical and safety monograph for AXTLE (AXTLE).
| Placental transfer | Crosses placenta (lipophilic, low molecular weight); fetal exposure confirmed. |
| Breastfeeding | Excreted into breast milk in low amounts; monitor infant for potential adverse effects; consider alternative if possible. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to active substanceSevere hepatic impairmentConcomitant use with MAOIs
| Precautions | Increased risk of infections, Allergic reactions including anaphylaxis, Exacerbation of autoimmune conditions, Potential for immunogenicity |
| Food/Dietary | Avoid grapefruit, grapefruit juice, and Seville oranges as they inhibit CYP3A4, increasing acalabrutinib exposure. No other significant food interactions. |
| Clinical Pearls | AXTLE (acalabrutinib) is a selective BTK inhibitor with fewer off-target effects than ibrutinib; monitor for atrial fibrillation, bleeding, and infections. Dose adjustment required with strong CYP3A4 inhibitors. Use with caution in hepatic impairment. |
Loading safety data…
| L3 |
| Teratogenic Risk | Pregnancy Category X. AXTLE is contraindicated in pregnancy due to documented teratogenicity in animal studies and case reports in humans. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and fetal renal impairment. Use is not recommended at any stage of pregnancy. |
| Fetal Monitoring | Monitor renal function (serum creatinine, BUN, urine output) and hepatic function (ALT, AST, bilirubin) throughout therapy. Perform serial fetal ultrasound for growth, amniotic fluid volume, and anatomy if inadvertent exposure occurs. Monitor maternal blood pressure and electrolytes. In lactating women, ensure complete cessation of breastfeeding. |
| Fertility Effects | AXTLE may impair fertility in both males and females based on animal studies showing reduced spermatogenesis and ovarian follicular development. Reversible upon discontinuation. Human data limited; advise reproductive counseling. |
| Patient Advice | Take AXTLE exactly as prescribed, usually twice daily with or without food. · Avoid grapefruit, grapefruit juice, and Seville oranges during treatment. · Report any signs of bleeding, bruising, or infection to your healthcare provider immediately. · Do not open, break, or chew the capsules; swallow whole. · Complete all vaccination series before starting treatment if possible. |